| Bioactivity | Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs[1][2][3][4][5][6]. |
| CAS | 90729-41-2 |
| Formula | C19H21NO6 |
| Molar Mass | 359.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Nyska A, et al. Gingival hyperplasia in rats induced by oxodipine‐a calcium channel blocker[J]. Journal of Periodontal Research, 1990, 25(2): 65-68. [2]. Tamargo J, et al. Effects of oxodipine on 45Ca movements and contractile responses in vascular smooth muscle[J]. British journal of pharmacology, 1989, 97(2): 339. [3]. Galán L, et al. Characteristics of Ca2+ channel blockade by oxodipine and elgodipine in rat cardiomyocytes[J]. European journal of pharmacology, 1998, 357(1): 93-105. [4]. Egros F, et al. An original intragastric delivery system for oral administration of solid formulations to fully conscious rats: its application to oxodipine studies[J]. European Journal of Drug Metabolism and Pharmacokinetics, 1991: 71-76. [5]. Montastruc P, et al. Effect of oxodipine, a novel dihydropyridine calcium channel blocker, in neurogenic hypertensive dogs[J]. Archives internationales de pharmacodynamie et de thérapie, 1993, 321: 57-62. [6]. Tejerina T, et al. Effects of oxodipine on isolated rabbit aorta and mesenteric resistance vessels[J]. European journal of pharmacology, 1992, 219(2): 279-284. |